Emerging evidence suggests widely used metabolic drugs could influence brain aging pathways, yet large clinical trials are still needed to confirm whether they truly alter the course of neurodegenerative disease.
Study: The promise of GLP-1 receptor agonists for neurodegenerative diseases. Image Credit: Antonio Marca / Shutterstock
In a recent review published in the Journal of Clinical Investigation, the authors examined the biological mechanisms, translational evidence, and clinical potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as disease-modifying therapies for neurodegenerative diseases (NDDs).
Background
By 2040, NDDs are projected to become the second leading cause of death worldwide, based on epidemiological modelling projections. Rates of Alzheimer’s disease, Parkinson’s…